Health-related quality of life analysis of the LEAP-002 study of lenvatinib plus pembrolizumab versus lenvatinib as first-line treatment for advanced hepatocellular carcinoma

By sjmartinez • May 29, 2025

Finn RS, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo BY, Ren Z, Cheng AL, Galle PR, Kaneko S, Kumada H, Kamble S, Norquist JM, Mody K, Wang A, Dubrovsky L, Llovet JM. Health-related quality of life analysis of the LEAP-002 study of lenvatinib plus pembrolizumab versus lenvatinib as first-line treatment for advanced hepatocellular carcinoma. ESMO Open. 2025 May 27;10(6):105065. doi: 10.1016/j.esmoop.2025.105065. Epub ahead of print. PMID: 40435872.

Ciprofloxacin and Metronidazole As Rare Culprits of Drug-Induced Immune Thrombocytopenia in the Setting of Diverticulitis Treatment

Tai JW, Young EH, Shah VD, Reed JP. Ciprofloxacin and Metronidazole As Rare Culprits of Drug-Induced Immune Thrombocytopenia in the Setting of Diverticulitis Treatment. Cureus.[...]

Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells

Li YR, Li Z, Zhu Y, Li M, Chen Y, Lee D, Ochoa CJ, Singh T, DiBernardo G, Guo W, Li S, Zhou Y, Yu[...]

Evaluating Asparaginase Toxicity in Hispanic Patients With Acute Lymphoblastic Leukemia in a Large Safety-Net Hospital

Zheng D, Dragan M, Jang J, Tomassetti S. Evaluating Asparaginase Toxicity in Hispanic Patients With Acute Lymphoblastic Leukemia in a Large Safety-Net Hospital. World J[...]